Minista10 mg

Minista 10 mg is a second-generation, non-sedating antihistamine prescribed for the symptomatic relief of allergic conditions in adults and children. It is indicated for the treatment of:

• Seasonal Allergic Rhinitis (SAR): Relieves sneezing, nasal itching, runny nose, and watery, itchy eyes triggered by seasonal allergens such as pollen.
• Perennial Allergic Rhinitis (PAR): Manages year-round nasal allergy symptoms caused by allergens like dust mites, mould, and pet dander.
• Urticaria (Hives): Reduces the itching, redness, and swelling associated with chronic and acute urticaria.

By controlling these symptoms, Rupatadine helps improve daily comfort and quality of life for people affected by allergic disorders.

Minista 10 mg belongs to the class of non-sedating antihistamines.

Rupatadine is a long-acting, non-sedating antagonist of histamine H1-receptors. Unlike conventional antihistamines, it also blocks the platelet-activating factor (PAF), giving it a distinctive dual mechanism of action.

Both histamine and PAF promote bronchoconstriction, increase vascular permeability, and act as key mediators in the inflammatory allergic response. By antagonizing both pathways simultaneously, Rupatadine delivers a stronger therapeutic effect than a single-target antihistamine.

Rupatadine also demonstrates additional anti-allergic and anti-inflammatory properties, including:

• Inhibition of mast cell degranulation triggered by both immunological and non-immunological stimuli.
• Suppression of the release of pro-inflammatory cytokines, particularly tumour necrosis factor alpha (TNF-α), in human mast cells and monocytes.

Clinically, the action begins within approximately 75 minutes of administration, with a duration of effect lasting around 8 to 10 hours, supporting convenient once-daily dosing.

Interaction with Medicines

• Co-administration of Rupatadine 20 mg with ketoconazole or erythromycin increases its systemic exposure. Caution is advised when used together with these agents or other inhibitors of the CYP3A4 isoenzyme.
• Rupatadine should be used cautiously alongside statins.
• Combining Rupatadine with CNS depressants or alcohol may increase the risk of drowsiness and requires caution.

Interaction with Food

• Grapefruit and grapefruit juice should not be consumed at the same time as Rupatadine, as they can raise blood levels of the drug.

Always inform your doctor about all prescription medicines, over-the-counter drugs, and supplements you are taking before starting Rupatadine.

Like all medicines, Minista 10 mg may cause side effects, although not everyone experiences them. Most effects are mild and temporary.

If any side effect becomes severe or persistent, or if signs of a serious allergic reaction occur, stop taking the medicine and seek medical attention promptly.

Pregnancy: There is no clinical data on the use of Rupatadine during pregnancy. Pregnant women should not use Rupatadine unless the expected benefit clearly outweighs the potential risk to the unborn baby, and only under a doctor's supervision.

Lactation: It is not known whether Rupatadine passes into breast milk. Therefore, it should not be used during breastfeeding unless the potential benefit to the mother justifies the possible risk to the infant. Consult your physician before use.

Before taking Minista 10 mg, inform your doctor of your full medical history. Extra caution is required in the following situations:

• Patients with known prolongation of the QT interval.
• Patients with uncorrected low potassium levels (hypokalaemia).
• Patients with ongoing proarrhythmic conditions, such as clinically significant slow heart rate (bradycardia) or acute myocardial ischaemia.
• Elderly patients aged 65 years and older, in whom the medicine should be used cautiously.
• Patients with impaired kidney or liver function — use of Rupatadine 10 mg tablets is currently not recommended in these patients due to a lack of clinical experience.

Because Rupatadine may cause dizziness or drowsiness in some people, take care when driving or operating machinery, and avoid alcohol during treatment.

The most commonly reported reaction following overdose is somnolence (excessive sleepiness). If accidental ingestion of a very high dose occurs, symptomatic treatment along with the necessary supportive measures should be provided. In case of suspected overdose, contact a doctor or the nearest emergency service immediately.

Store in a cool and dry place below 30°C, protected from light and moisture. Keep the medicine out of the reach and sight of children. Do not use beyond the printed expiry date.

• Elderly: Rupatadine should be used with caution in elderly patients. No data indicates a need for dose adjustment in this group.
• Children: The safety and efficacy of Rupatadine have not been established in patients younger than 12 years for the tablet form; paediatric dosing applies only to the oral solution as directed.
• Patients with renal or hepatic insufficiency: Use of Rupatadine is not recommended in patients with kidney or liver impairment, as no relevant clinical data is available.

Non-sedating antihistamines

Minista 10 mg is a long-acting, non-sedative antagonist of histamine H1-receptors. It also antagonizes the platelet activating factor (PAF). Both histamine and PAF cause broncho constriction which leads to an increase in the vascular permeability and act as a mediator in the inflammatory process. With the dual mode of action, Rupatadine shows better therapeutic effect than an isolated antihistamine. Rupatadine possesses other anti allergic properties such as the inhibition of the degranulation of mast cells induced by immunological and non immunological stimuli and inhibition of the release of cytokines, particularly of the tumor necrosis factor alpha (TNF α) in human mastocytes and monocytes.

There is no clinical data available on the exposure of Rupatadine during pregnancy. Pregnant women should therefore not use Rupatadine unless the potential benefit outweighs the potential risk for the infant. No information is available, whether Rupatadine is excreted in the mother's milk. Therefore, it should not be used during lactation, unless the potential benefits for the mother justify the potential risk to the infant.

Elderly: Rupatadine should be used with caution in elderly. No information is available that indicates the requirement of any dose adjustment in this population.Children: Neither the safety nor the efficacy of Rupatadine has been established in patients less than 12 years of age.Patients with renal or hepatic insufficiency: Use of Rupatadine is not recommended in patients with renal or hepatic insufficiency. As no relevant clinical data is available.